Next Article in Journal
Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document
Next Article in Special Issue
Extracellular and Intracellular Magnesium Deficiency Found in Pregnant Women with Preeclampsia and Gestational Diabetes Is Associated with Overexpression of Notch Proteins, Cytokines, p53, NF-kB and Proto-Oncogenes: Potential Importance in Growth Retardation, Stillbirths, Fetal Mutations and Increased Cardiovascular Risks and Stroke with Advancing Age in Pregnant Women
Previous Article in Journal
Heart Rate Variability Relates with Competition Performance in Professional Soccer Players
Previous Article in Special Issue
Preface to Hearts Special Issue “Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction”
Open AccessReview

Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors

Division of Pediatric Cardiology, Children’s National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA
*
Author to whom correspondence should be addressed.
Received: 24 November 2020 / Revised: 31 December 2020 / Accepted: 5 January 2021 / Published: 15 January 2021
(This article belongs to the Special Issue Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction)
Advances in pediatric cancer therapies have dramatically improved the likelihood of survival. As survivors are aging, however, we are now understanding that treatment carries a significant risk of cardiovascular toxicity, which can develop immediately, or even many years after completing therapy. Anthracycline derivates are some of the most commonly used agents in pediatric oncology treatment protocols, which have a dose-dependent correlation with the development of cardiac toxicity. As we learn more about the mechanisms of toxicity, we are developing prevention strategies, including improvements in surveillance, to improve early diagnosis of heart disease. Current survivorship surveillance protocols often include screening echocardiograms to evaluate systolic function by measuring the ejection fraction or fractional shortening. However, these measurements alone are not enough to capture early myocardial changes. The use of additional imaging biomarkers, serum biomarkers, electrocardiograms, as well as cholesterol and blood pressure screening, are key to the early detection of cardiomyopathy and cardiovascular disease. Medical treatment strategies are the same as those used for heart failure from other causes, but earlier recognition and implementation can lead to improved long term outcomes. View Full-Text
Keywords: cardio-oncology; cardiomyopathy; pediatric; anthracycline toxicity; chemotherapy; surveillance cardio-oncology; cardiomyopathy; pediatric; anthracycline toxicity; chemotherapy; surveillance
Show Figures

Figure 1

MDPI and ACS Style

Curren, V.; Dham, N.; Spurney, C. Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors. Hearts 2021, 2, 45-60. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010005

AMA Style

Curren V, Dham N, Spurney C. Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors. Hearts. 2021; 2(1):45-60. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010005

Chicago/Turabian Style

Curren, Valerie; Dham, Niti; Spurney, Christopher. 2021. "Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors" Hearts 2, no. 1: 45-60. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010005

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop